Phase I/II study of oral fluoropyrimidine S-1 plus oral Leucovorin as first-line treatment for metastatic colorectal cancer

被引：0
|
作者：
Yoshino, T.
Koizumi, W.
Yamaguchi, K.
Miyata, Y.
Kato, T.
Toh, Y.
Sawaki, A.
Hyodo, I.
Nishina, T.
Boku, N.
机构：
[1] Shizuoka Canc Ctr, Shizuoka, Japan
[2] Kitasato Univ, East Hosp, Sagamihara, Kanagawa, Japan
[3] Saitama Canc Ctr, Saitama, Japan
[4] Saku Cent Hosp, Nagano, Japan
[5] Minoh City Hosp, Osaka, Japan
[6] Natl Kyushu Canc Ctr, Fukuoka, Fukuoka, Japan
[7] Aichi Canc Ctr, Nagoya, Aichi, Japan
[8] Univ Tsukuba, Tsukuba, Ibaraki, Japan
[9] NHO Shikoku Canc Ctr, Matsuyama, Ehime, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4093
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
    Nishina, Tomohiro
    Kato, Takeshi
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Boku, Narikazu
    Hyodo, Ichinosuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (03) : 547 - 553
  • [22] A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
    Tomohiro Nishina
    Takeshi Kato
    Kentaro Yamazaki
    Takayuki Yoshino
    Yoshinori Miyata
    Taito Esaki
    Toshikazu Moriwaki
    Narikazu Boku
    Ichinosuke Hyodo
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 547 - 553
  • [23] Phase I study of alternate-day administration of S-1, oral leucovorin, and bevacizumab for refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Komori, Azusa
    Mitani, Seiichiro
    Hasegawa, Hiroko
    Narita, Yukiya
    Kadowaki, Shigenori
    Ura, Takashi
    Ando, Masashi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment
    David J Kerr
    Nature Clinical Practice Oncology, 2008, 5 : 250 - 251
  • [25] Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment
    Kerr, D. J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (05): : 250 - 251
  • [26] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    Hoff, PM
    Ansari, R
    Batist, G
    Cox, J
    Kocha, W
    Kuperminc, M
    Maroun, J
    Walde, D
    Weaver, C
    Harrison, E
    Burger, HU
    Osterwalder, B
    Wang, AO
    Wong, R
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2282 - 2292
  • [27] The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer
    Nakamura, Masato
    Yamada, Yasuhide
    Muro, Kei
    Takahashi, Keiichi
    Baba, Hideo
    Sasaki, Yasutsuna
    Komatsu, Yoshito
    Satoh, Taroh
    Mishima, Hideyuki
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    FUTURE ONCOLOGY, 2015, 11 (10) : 1471 - 1478
  • [28] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
    J-P Delord
    J Bennouna
    P Artru
    H Perrier
    F Husseini
    F Desseigne
    E François
    R Faroux
    D Smith
    P Piedbois
    H Naman
    J Y Douillard
    R Bugat
    British Journal of Cancer, 2007, 97 : 297 - 301
  • [30] A randomized Phase II study of tegafur/uracil (UFT), oral Leucovorin and irinotecan, combination therapy (TEGAFIRI) plus bevacizumab versus FOLFIRI plus bevacizumab for the first-line treatment of patients with metastatic colorectal cancer
    Hasegawa, H.
    Endo, T.
    Ochiai, D.
    Uchida, H.
    Okabayashi, T.
    Imai, S.
    Ishii, Y.
    Tsuruta, M.
    Kitagawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
12345